While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

Researchers have pioneered a novel 3D platform that mimics the human bone marrow and immune environment, enabling more ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

Researchers at the University of California Davis Comprehensive Cancer Center have uncovered an evolutionary change that may ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...